Results 131 to 140 of about 246,923 (261)

Treatment of grass pollen allergy: focus on a standardized grass allergen extract – Grazax®

open access: yes, 2008
Moisés Calderón1, Tove Brandt21Section of Allergy and Clinical Immunology, Royal Brompton Hospital, Imperial College, NHLI, London, UK; 2Group Clinical Development, ALK-Abelló A/S, Hørsholm, DenmarkAbstract ...
Tove Brandt   +1 more
core  

The lung is more than an organ of gas exchange: immunocompetency, platelets and implications for drug discovery

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The lungs have for a long time been recognised as having pharmacological significance as a specific organ to modulate the pharmacokinetics of endogenous substances needed to maintain homeostasis. The lungs are therefore the site of action of certain drugs that act on these homeostatic processes, resulting in systemic effects on the ...
Simon C. Pitchford
wiley   +1 more source

MCL‐1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Myeloid cell leukaemia‐1 (MCL‐1) is an essential anti‐apoptotic protein and a promising therapeutic target in oncology. Early clinical studies of MCL‐1 inhibitors reported unexpected elevations in cardiac troponin, raising concerns about potential cardiotoxicity.
Markus B. Heckmann   +7 more
wiley   +1 more source

Are Markers of Allergic Inflammation in Grass Pollen Allergy Influenced by H1 Antihistamines? [PDF]

open access: yesJ Clin Med, 2021
Bocsan IC   +7 more
europepmc   +1 more source

Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study

open access: yesClinical &Experimental Allergy, Volume 55, Issue 3, Page 226-238, March 2025.
In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.
Bernardo Sousa‐Pinto   +121 more
wiley   +1 more source

Nonpharmacological measures to prevent allergic symptoms in pollen allergy: A critical review. [PDF]

open access: yesAllergol Select, 2021
Bergmann KC   +6 more
europepmc   +1 more source

Prevalence and Sociodemographic Variation of Allergic Diseases in Australia: Findings From the Australian National Health Survey

open access: yesClinical &Experimental Allergy, EarlyView.
Using data from 17,093 participants in the 2022 Australian National Health Survey, this study is the first to report nationwide prevalence estimates for allergic rhinitis (23.9%), food allergy (7.0%), drug allergy (5.2%), eczema (1.6%) and diagnosed asthma (10.8%) across Australia.
Yichao Wang   +14 more
wiley   +1 more source

Three cases of jackfruit allergy in Canada: a case series

open access: yesAllergy, Asthma & Clinical Immunology
Jackfruit allergies have been rarely reported in the literature. In this case series, three case reports of jackfruit allergy in British Columbia, Canada are presented.
Faith Wierenga, Manstein Kan
doaj   +1 more source

Monitoring, distribution and clinical relevance of airborne pollen and fern spores in Southeast Asia – A systematic review

open access: yesWorld Allergy Organization Journal
Southeast Asia is witnessing a rapid increase in the prevalence of allergic diseases, including asthma and allergic rhinitis. Pollen grains stand out as one of the primary triggers for allergy, and monitoring aeroallergens plays a pivotal role in allergy
Ngoc Thi Pham, MSc   +3 more
doaj   +1 more source

FOOD ALLERGY AND BIRCH POLLEN: MOLECULAR MECHANISMS AND IMMUNOTHERAPY POSSIBILITIES [PDF]

open access: yes
Introduction and Aim of the Study: During the birch pollen season, cross-reactions between the allergen Bet v 1 and the Mal d 1 allergen from apples can induce pollen-related food allergy (prFA), particularly after apple consumption.
Aleksandra Sagan   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy